Assessment of Real-World Outcomes Associated With Afatinib (Gilotrif) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 15 Feb 2021 New trial record